🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

New Review - Parigi et al - Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting thelancet.com/journals/langa… #GITwitter #IBD Silvio Danese Laurent Peyrin-Biroulet Maria T. Abreu Vipul Jairath MBChB DPhil David T. Rubin, MD IOIBD

Proud to work in Università Vita-Salute San Raffaele Ospedale San Raffaele which again ranked 2/45 in Italy and 89 among world medical universities. 40 of our scientists have an Hindex >70 (Google Scholar). Just the tip of the iceberg of 200 great Professors research.com/university/med…

New insights into IBD trials! "Washout periods in inflammatory bowel disease trials: A systematic literature review and proposed solutions" Vipul Jairath MBChB DPhil Bruce E. Sands Silvio Danese pubmed.ncbi.nlm.nih.gov/37743039/

Glad to see our Review on “Gut virome in inflammatory bowel disease and beyond” in collaboration with Federica Ungaro Luca Massimino Tommaso Lorenzo Parigi et al now online Gut Journal gut.bmj.com/content/early/… Hein M. Tun Daniel Zhen Ye Sin Microbiota I-Center CUHK Medicine

CD and UC indices are similarly reliable and responsive in measuring histologic CD activity. Find out more in our latest work: pubmed.ncbi.nlm.nih.gov/38056798/ Vipul Jairath MBChB DPhil Remo Panaccione, MD, FRCPC Christopher Ma MD MPH Silvio Danese Laurent Peyrin-Biroulet Bruce E. Sands Britt Christensen, MBBS MPH PhD

Virginia Solitano Vipul Jairath MBChB DPhil Remo Panaccione, MD, FRCPC Christopher Ma MD MPH Silvio Danese Laurent Peyrin-Biroulet Bruce E. Sands Britt Christensen, MBBS MPH PhD Super Virginia Solitano ! You are a rising star in the IBD world!

Congratulations to Virginia Solitano for leading this work during your IBD fellowship Western University Schulich WesternU

New Research - Danese et al - Efficacy and safety of 48 weeks of guselkumab for patients with Crohn’s disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial thelancet.com/journals/langa… #IBD #GITwitter Silvio Danese

Check out our “Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study” Silvio Danese Laurent Peyrin-Biroulet Vipul Jairath MBChB DPhil sciencedirect.com/science/articl…

Tra cenoni, pranzi, aperitivi e brindisi per molti le feste natalizie si trasformano in una vera e propria maratona alimentare che può mettere in difficoltà stomaco e intestino. Ne parliamo con SILVIO DANESE, Dir. Gastroenterologia IRCCS Ospedale San Raffaele e AMBRA CILIBERTO, Dietista

La pancia lo sa, quanto è vero. Ancora per qualche giorno è in edicola, con il mensile Focus e con il settimanale Tv Sorrisi e canzoni, il libro di Silvio Danese, primario di gastroenterologia al Ospedale San Raffaele Collana Scienze per la vita (Sonzogno)

#GUTImage from the #RecentAdvancesInBasicScience paper by @thetunlab et al "Gut virome in inflammatory bowel disease and beyond" via bit.ly/3SfdusW Luca Massimino Silvio Danese #IBD

Apply now for the UEG Clinical Visiting Fellowship program! Don't miss the chance to spend 2 weeks in Milan 🇮🇹 at the IBD center of Ospedale San Raffaele with Prof. Danese Silvio Danese and all the experts. ➡️ueg.eu/opportunities/…

Thrilled to kick off #Takeda's Australia tour in #Brisbane as the local speaker! Prof. Silvio Danese dazzled us with his talk on 'Diving into Deeper Remission in UC'—no snorkel needed! Big thanks to Gareth Walker for expertly steering the session and to Takeda for organizing.

1 in 4 IBD in tertiary centers is difficult to treat. Time to focus research where is most needed. Find out more at: academic.oup.com/ecco-jcc/artic…

Let’s dive in the management of IBD in the next 5 years ! Kicking off the session on future IBD with Silvio Danese, showing us the pipeline and carousel of novel IBD drugs to come!

Silvio Danese presents 52 week data for tamuzimod for moderately to severely active ulcerative colitis #GITwitter #UEGWeek #UEGWeek2024 #IBD

Both doses of tamuzimod studied were significantly superior to placebo for clinical and endoscopic remission. Secondary outcomes shown below #UEGWeek #UEGWeek2024 #GITwitter #IBD

Read the latest #GUTBlog on the #RecentAdvancesInClinicalPractice paper by Sailish Honap et al entitled "Acute severe ulcerative colitis trials: the past, the present and the future" via bit.ly/3BAY3pn Paper via: bit.ly/47YQN2L Vipul Jairath MBChB DPhil Silvio Danese

Report from compassionate program in Italy. Upadacitinib in patients with difficult-to treat Crohn’s disease | Crohn's & Colitis 360 | Oxford Academic ⁦Cristina Bezzio⁩ ⁦Federica⁩ ⁦Edoardo Savarino⁩ ⁦Silvio Danese⁩ academic.oup.com/crohnscolitis3…